A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Inclusion Criteria:

- Patients must have persistent or recurrent epithelial ovarian, primary peritoneal, or
fallopian tube carcinoma, with histologic confirmation of the original primary tumor.

- Must have had at least one prior platinum-based (cisplatin or carboplatin)
chemotherapy regimen for the management of their primary disease. This would include
intraperitoneal chemotherapy.

- Patients must be considered platinum refractory or resistant, defined as patients
with progression of disease during platinum-based chemotherapy, patients having
persistent disease at the completion of platinum-based chemotherapy, or patients
having a disease free interval following prior platinum therapy of less than 6
months.

- Patients may have had no more than 3 prior treatment regimens for their epithelial
ovarian, primary peritoneal or fallopian tube carcinoma. Consolidation or maintenance
therapy initiated within 6 weeks of the completion of primary therapy will not be
counted as an additional regimen.

- Must have measurable disease by RECIST 1.1 criteria.

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

- Time interval from last chemotherapy, radiotherapy, or surgery of at least four weeks
and the patient must have recovered from any significant adverse effects of prior
treatment. Patients must be ≥ 6 weeks from having received nitrosoureas or mitomycin
C.

- Life expectancy > 3 months

- Patient must have adequate bone marrow and organ function, as defined below:

- Leukocyte count ≥ 3 x 10^9/L

- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

- Platelet count ≥ 100 x 10^9/L

- Total bilirubin within normal institutional limits

- Aspartic transaminase (AST [SGOT])/alanine transaminase (ALT [SGPT]) ≤ 2.5 x
institutional upper limits of normal (ULN)

- Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance (ClCr) ≥ 60 ml/min by
Cockcroft Gault method

- Patients must have signed an approved informed consent.

- Patients of childbearing potential must have a negative serum pregnancy test prior to
study entry and must use an effective form of contraception.

- Patients must have archival tissue available from their original tumor debulking
surgery for assessment of BRCA1 protein expression.

Exclusion Criteria:

- Patients with borderline ovarian tumors, ovarian germ cell tumors, ovarian sex-cord
stromal tumors, or other non-epithelial ovarian tumors are not eligible.

- Patients receiving any other investigational agents

- Patients who have received radiation therapy to more than 25% of the bone marrow

- Patients who have previously received SJG-136 or related compounds

- Uncontrolled intercurrent illness including, but not limited to, ongoing active
infection, symptomatic congestive heart failure, unstable angina pectoris,
uncontrolled cardiac arrhythmias, or psychiatric illness/social situations that would
limit compliance with the study requirements

- Prior malignancy (other than cervical carcinoma in situ, ductal carcinoma in situ of
the breast, or non-melanoma skin cancer) unless treated with curative intent and
without evidence of disease for 3 years

- With the exception of alopecia (or other situations in which the organ dysfunction or
symptoms are considered clinically insignificant or irrelevant to the study),
patients may not have baseline organ dysfunction or symptoms that qualify as grade 2
or higher by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria
for Adverse Events (CTCAE) v4.0. Particular attention should be paid to assessment of
pre-existing edema, since vascular leak syndrome was the dose limiting toxicity of
this agent in the phase I trial.